The News

Innate Pharma updates its financials and reports operating revenues of 14.2 million euros for 2007.

06/02/2008

Marseilles, February 6, 2008
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), a biopharmaceutical company developing first-in-class drugs targeting the innate immune system, today announces an operating revenue of 14.2 million euros in 2007. Turnover for the year amounted to 8.7 million euros, including 3.6 million euros in the fourth quarter ended December 31, 2007.

 

2008

Click here for the site of Sofinnova Ventures, our sister firm in San Francisco http://www.sofinnova.com